Teva Pharmaceutical Industries (TEVA) Exchange Rate Effect (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Exchange Rate Effect across 10 years of filings, most recently posting -$17.0 million for Q1 2026.

• Quarterly Exchange Rate Effect fell 137.78% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.0 million (down 64.0% YoY) and the FY2025 annual result came in at $21.0 million, up 112.07% from the prior year.
• Exchange Rate Effect declined to -$17.0 million in Q1 2026, from -$10.0 million in the prior quarter.
• Over five years, Exchange Rate Effect peaked at $146.0 million in Q4 2022 and troughed at -$123.0 million in Q2 2022.
• A 5-year average of -$19.0 million and a median of -$17.0 million in 2026 frame the typical range for Exchange Rate Effect.
• Biggest YoY gain for Exchange Rate Effect was 404.17% in 2022; the steepest drop was 2360.0% in 2022.
• Tracing TEVA's Exchange Rate Effect over 5 years: stood at $146.0 million in 2022, then sank by 53.42% to $68.0 million in 2023, then plunged by 277.94% to -$121.0 million in 2024, then jumped by 91.74% to -$10.0 million in 2025, then plunged by 70.0% to -$17.0 million in 2026.
• Business Quant data shows TEVA's Exchange Rate Effect at -$17.0 million in Q1 2026, -$10.0 million in Q4 2025, and -$9.0 million in Q3 2025.